Cervical Squamous Cell Carcinoma Clinical Trial
Official title:
A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix
This phase II trial is studying erlotinib to see how well it works in treating patients with persistent or recurrent cancer of the cervix. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor
Status | Completed |
Enrollment | 51 |
Est. completion date | |
Est. primary completion date | November 2005 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed squamous cell carcinoma (SCC) of the cervix - Persistent or recurrent progressive disease - At least 1 prior systemic chemotherapy regimen for management of advanced, metastatic, or recurrent SCC of the cervix is required - Chemotherapy administered as a radiosensitizer in conjunction with radiotherapy does not count as a systemic chemotherapy regimen - At least 1 unidimensionally measurable target lesion - At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan - Lesions within a previously irradiated field are considered nontarget lesions unless disease progression or persistence is confirmed = 90 days after completion of radiotherapy - Tumor accessible for repeat needle biopsy - Ineligible for a higher priority Gynecologic Oncology Group (GOG) protocol (any active GOG phase III protocol for the same patient population) - Performance status - GOG 0-2 (for patients who have received only 1 prior regimen) - Performance status - GOG 0-1 (for patients who have received 2 prior regimens) - Platelet count at least 100,000/mm^3 - Absolute neutrophil count at least 1,500/mm^3 - Bilirubin no greater than upper limit of normal (ULN) - SGOT no greater than 2.5 times ULN - Alkaline phosphatase no greater than 2.5 times ULN - Creatinine no greater than 1.5 times ULN - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia - No abnormalities of the cornea (e.g., dry eye syndrome or Sjogren's syndrome) - No congenital abnormalities (e.g., Fuch's dystrophy) - No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose) - No abnormal corneal sensitivity test (Schirmer test or similar tear production test) - No other invasive malignancy within the past 5 years except nonmelanoma skin cancer - No uncontrolled concurrent illness - No ongoing or active infection requiring IV antibiotics - No psychiatric illness or social situation that would preclude study compliance - No grade 2 or greater sensory or motor neuropathy - No prior allergic reactions attributed to compounds of similar chemical or biological composition to erlotinib - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - HIV negative - At least 3 weeks since prior immunologic therapy for SCC of the cervix - One additional prior cytotoxic chemotherapy regimen for recurrent or persistent disease allowed - At least 3 weeks since prior chemotherapy for SCC of the cervix and recovered - No prior non-cytotoxic chemotherapy for recurrent or persistent disease - At least 3 weeks since prior hormonal therapy for SCC of the cervix - At least 3 weeks since prior radiotherapy for SCC of the cervix and recovered - Recovered from recent prior surgery - At least 3 weeks since other prior therapy for SCC of the cervix - No prior epidermal growth factor receptor-targeting therapies - No prior anticancer treatment that would preclude study participation - No other concurrent investigational or commercial agents or therapies for SCC of the cervix |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Gynecologic Oncology Group | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival | At 6 months | No | |
Primary | Frequency and severity of adverse effects as measured by NCI CTC version 3.0 | Up to 5 years | Yes | |
Secondary | Duration of overall survival | Up to 5 years | No | |
Secondary | Duration of progression-free survival | Up to 5 years | No | |
Secondary | Frequency of clinical response (complete and partial) | Up to 5 years | No | |
Secondary | Prognostic factors including initial performance status and age | Up to 5 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05013268 -
Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma
|
Phase 1 | |
Completed |
NCT02562729 -
Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer
|
Phase 2 | |
Completed |
NCT00416455 -
Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00054444 -
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
|
Phase 1 | |
Recruiting |
NCT05210348 -
Clinical Evaluation of Detection of High Risk HPV in Urine
|
||
Completed |
NCT01759355 -
Hybrid PET/MR in the Therapy of Cervical Cancer
|
||
Completed |
NCT00068549 -
Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03983954 -
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT00559377 -
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
|
Phase 2 | |
Completed |
NCT00309959 -
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05613283 -
Primary Cervical Cancer Screening by Self-sampling HPV Test
|
||
Completed |
NCT00064077 -
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
|
Phase 3 | |
Active, not recruiting |
NCT02466971 -
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
|
Phase 3 | |
Completed |
NCT02164461 -
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
|
Phase 1 | |
Completed |
NCT01807546 -
Oral Rigosertib for Squamous Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT01649089 -
Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
|
N/A | |
Completed |
NCT00499031 -
Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer
|
Phase 2 | |
Terminated |
NCT00070317 -
Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer
|
N/A | |
Not yet recruiting |
NCT04976478 -
Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma
|
||
Active, not recruiting |
NCT03738228 -
Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
|
Phase 1 |